v3.26.1
SEGMENT INFORMATION (Tables)
 9 Months Ended
Jul. 31, 2026
Segment Reporting [Abstract]  
Segment Profitability and Segment Assets
The following tables reflect segment results under our management reporting system after excluding certain unallocated costs as noted in the reconciliations below:
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Three Months Ended July 31, 2026:
Net Revenue$746 $786 $346 $1,878 
Segment Expenses (1)
Cost of products and services332 338 148 
Research and development66 28 24 
Selling, general and administrative172 150 88 
Reportable segment income from operations$176 $270 $86 $532 
Three Months Ended July 31, 2025:
Net Revenue$670 $744 $324 $1,738 
Segment Expenses (1)
Cost of products and services332 334 150 
Research and development61 26 23 
Selling, general and administrative159 136 80 
Reportable segment income from operations$118 $248 $71 $437 
(1) Share-based compensation expense and depreciation expense included in segment expenses are shown below:
Share-Based Compensation ExpenseDepreciation Expense
Three Months Ended July 31,
Three Months Ended July 31,
2026202520262025
(in millions)(in millions)
Life Sciences and Diagnostics Markets$11 $8 $24 $25 
Agilent CrossLab$12 $9 $14 $14 
Applied Markets$5 $4 $6 $6 
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Nine Months Ended July 31, 2026:
Net Revenue$2,157 $2,303 $1,051 $5,511 
Segment Expenses (1)
Cost of products and services1,005 1,016 457 
Research and development195 84 72 
Selling, general and administrative511 451 263 
Reportable segment income from operations$446 $752 $259 $1,457 
Nine Months Ended July 31, 2025:
Net Revenue$1,971 $2,153 $963 $5,087 
Segment Expenses (1)
Cost of products and services946 957 440 
Research and development183 79 69 
Selling, general and administrative478 417 240 
Reportable segment income from operations$364 $700 $214 $1,278 
(1) Share-based compensation expense and depreciation expense included in segment expenses are shown below:
Share-Based Compensation ExpenseDepreciation Expense
Nine Months Ended July 31,
Nine Months Ended July 31,
2026202520262025
(in millions)(in millions)
Life Sciences and Diagnostics Markets$36 $32 $76 $72 
Agilent CrossLab$40 $36 $42 $42 
Applied Markets$18 $17 $19 $18 
Reconciliation of segment results to total enterprise results
The following table reconciles reportable segments' income from operations to Agilent’s total enterprise income before taxes: 
Three Months EndedNine Months Ended
July 31,July 31,
2026202520262025
(in millions)
Total reportable segment income from operations$532 $437 $1,457 $1,278 
Unallocated costs:
Amortization of intangible assets related to business combinations(21)(26)(59)(81)
Acquisition and integration costs(7)(3)(22)(15)
Transformational initiatives(37)(18)(95)(48)
Restructuring and other related costs(15)(17)(43)(74)
Other(8)(13)(42)(24)
Total unallocated costs(88)(77)(261)(242)
Income from operations444 360 1,196 1,036 
Interest income15 16 43 45 
Interest expense(29)(28)(79)(85)
Other income (expense), net14 18 56 (3)
Income before taxes, as reported$444 $366 $1,216 $993